Literature DB >> 24662536

Parkinson disease: Gene therapy for Parkinson disease--a hope, or a dream?

C Warren Olanow1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24662536     DOI: 10.1038/nrneurol.2014.45

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  10 in total

1.  A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency.

Authors:  Salima Hacein-Bey-Abina; Christof von Kalle; Manfred Schmidt; Françoise Le Deist; Nicolas Wulffraat; Elisabeth McIntyre; Isabelle Radford; Jean-Luc Villeval; Christopher C Fraser; Marina Cavazzana-Calvo; Alain Fischer
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

2.  Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial.

Authors:  William J Marks; Raymond T Bartus; Joao Siffert; Charles S Davis; Andres Lozano; Nicholas Boulis; Jerrold Vitek; Mark Stacy; Dennis Turner; Leonard Verhagen; Roy Bakay; Raymond Watts; Barton Guthrie; Joseph Jankovic; Richard Simpson; Michele Tagliati; Ron Alterman; Matthew Stern; Gordon Baltuch; Philip A Starr; Paul S Larson; Jill L Ostrem; John Nutt; Karl Kieburtz; Jeffrey H Kordower; C Warren Olanow
Journal:  Lancet Neurol       Date:  2010-10-20       Impact factor: 44.182

3.  Disease duration and the integrity of the nigrostriatal system in Parkinson's disease.

Authors:  Jeffrey H Kordower; C Warren Olanow; Hemraj B Dodiya; Yaping Chu; Thomas G Beach; Charles H Adler; Glenda M Halliday; Raymond T Bartus
Journal:  Brain       Date:  2013-08       Impact factor: 13.501

Review 4.  Open-label surgical trials for Parkinson disease: time for reconsideration.

Authors:  Ron L Alterman; Michele Tagliati; C Warren Olanow
Journal:  Ann Neurol       Date:  2011-07       Impact factor: 10.422

5.  Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial.

Authors:  Stéphane Palfi; Jean Marc Gurruchaga; G Scott Ralph; Helene Lepetit; Sonia Lavisse; Philip C Buttery; Colin Watts; James Miskin; Michelle Kelleher; Sarah Deeley; Hirokazu Iwamuro; Jean Pascal Lefaucheur; Claire Thiriez; Gilles Fenelon; Cherry Lucas; Pierre Brugières; Inanna Gabriel; Kou Abhay; Xavier Drouot; Naoki Tani; Aurelie Kas; Bijan Ghaleh; Philippe Le Corvoisier; Patrice Dolphin; David P Breen; Sarah Mason; Natalie Valle Guzman; Nicholas D Mazarakis; Pippa A Radcliffe; Richard Harrop; Susan M Kingsman; Olivier Rascol; Stuart Naylor; Roger A Barker; Philippe Hantraye; Philippe Remy; Pierre Cesaro; Kyriacos A Mitrophanous
Journal:  Lancet       Date:  2014-01-10       Impact factor: 79.321

6.  AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial.

Authors:  Peter A LeWitt; Ali R Rezai; Maureen A Leehey; Steven G Ojemann; Alice W Flaherty; Emad N Eskandar; Sandra K Kostyk; Karen Thomas; Atom Sarkar; Mustafa S Siddiqui; Stephen B Tatter; Jason M Schwalb; Kathleen L Poston; Jaimie M Henderson; Roger M Kurlan; Irene H Richard; Lori Van Meter; Christine V Sapan; Matthew J During; Michael G Kaplitt; Andrew Feigin
Journal:  Lancet Neurol       Date:  2011-04       Impact factor: 44.182

Review 7.  Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications.

Authors:  C Warren Olanow; Jose A Obeso; Fabrizio Stocchi
Journal:  Lancet Neurol       Date:  2006-08       Impact factor: 44.182

8.  Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains.

Authors:  Raymond T Bartus; Christopher D Herzog; Yaping Chu; Alistair Wilson; Lamar Brown; Joao Siffert; Eugene M Johnson; C Warren Olanow; Elliott J Mufson; Jeffrey H Kordower
Journal:  Mov Disord       Date:  2010-11-18       Impact factor: 10.338

9.  α-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons.

Authors:  Mickael Decressac; Banafsheh Kadkhodaei; Bengt Mattsson; Ariadna Laguna; Thomas Perlmann; Anders Björklund
Journal:  Sci Transl Med       Date:  2012-12-05       Impact factor: 17.956

10.  Results from a phase I safety trial of hAADC gene therapy for Parkinson disease.

Authors:  J L Eberling; W J Jagust; C W Christine; P Starr; P Larson; K S Bankiewicz; M J Aminoff
Journal:  Neurology       Date:  2008-04-09       Impact factor: 9.910

  10 in total
  3 in total

Review 1.  Back to the future with phenotypic screening.

Authors:  Marguerite Prior; Chandramouli Chiruta; Antonio Currais; Josh Goldberg; Justin Ramsey; Richard Dargusch; Pamela A Maher; David Schubert
Journal:  ACS Chem Neurosci       Date:  2014-06-05       Impact factor: 4.418

Review 2.  Neurotransmitter release: vacuolar ATPase V0 sector c-subunits in possible gene or cell therapies for Parkinson's, Alzheimer's, and psychiatric diseases.

Authors:  Haruhiro Higashida; Shigeru Yokoyama; Chiharu Tsuji; Shin-Ichi Muramatsu
Journal:  J Physiol Sci       Date:  2016-06-11       Impact factor: 2.781

3.  Comparative Analysis of the Effects of Neurotrophic Factors CDNF and GDNF in a Nonhuman Primate Model of Parkinson's Disease.

Authors:  Enrique Garea-Rodríguez; Ave Eesmaa; Päivi Lindholm; Christina Schlumbohm; Jessica König; Birgit Meller; Kerstin Krieglstein; Gunther Helms; Mart Saarma; Eberhard Fuchs
Journal:  PLoS One       Date:  2016-02-22       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.